Worth reading
46Recurring
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
9.6
%Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales15,088¥ millionYear on year +9.6%
Operating profit28¥ millionYear on year +23.1%
Ordinary income28¥ millionYear on year +6.8%
Net income attributable to owners of the parent17¥ millionYear on year +162.0%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
Net income per share¥1.67
Financial position at period-end
Total assets25,121¥ million
of which net assets 8,350 ¥ millionEquity ratio 33.2%vs. prior year-end -2.2pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueArrhythmia business ¥12,343,924 thousand (YoY +9.7%), Ischemia business ¥1,072,735 thousand (YoY +12.1%), Other ¥1,672,074 thousand (YoY +7.2%)
Segment profitArrhythmia business ¥1,100,966 thousand (YoY +7.9%), Ischemia business ¥119,327 thousand (YoY +7.7%), Other ¥215,449 thousand (YoY +17.7%)
Outlook and shareholder returns
Full-year earnings forecast
Net SalesNot disclosed
Operating profitNot disclosed
Ordinary incomeNot disclosed
Net incomeNot disclosed
ReasonNo consolidated earnings forecast is provided because the Company's shares are scheduled to be delisted on 28 August 2026.
Annual Dividend Forecast¥50.00 → Not disclosed
Factors Behind Changes in Business Performance
Although selling, general and administrative expenses increased due to costs related to the management integration and personnel expenses resulting from wage increases, sales of catheters for PF ablation were strong. In the Arrhythmia business, sales of catheters for PF ablation were strong; in the Ischemia business, sales of balloon catheters and the RAQUOS injection system were strong; and in Other, sales of structural heart products, including TAVI products, were strong.
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 / Name of newly added company Not disclosed / Excluded 0 / Excluded Company Name Not disclosed
Material subsequent eventsNo applicable matters.
Impairment lossNone recorded (no applicable matter)
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥2,168 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥0 thousand
Depreciation and amortization¥262,303 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNone (対象者：Not applicable)
Issued Shares at Period-End10,780,000 shares
Treasury Shares at Period-End279,044 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥15,088 million (YoY +9.6%) |
| Operating profit | ¥28 million (YoY +23.1%) |
| Ordinary income | ¥28 million (YoY +6.8%) |
| Profit attributable to owners of the parent | ¥17 million (YoY +162.0%) |
| Net income per share | ¥1.67 |
| Equity ratio | End of the current fiscal period 33.2% / End of previous period 35.4% |
| Total assets | ¥25,121 million |
| Net assets | ¥8,350 million |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Reason No consolidated earnings forecast is provided because the Company's shares are scheduled to be delisted on 28 August 2026. |
| Annual Dividend Forecast | ¥50.00 → Not disclosed |
| Segment revenue | Arrhythmia business ¥12,343,924 thousand (YoY +9.7%), Ischemia business ¥1,072,735 thousand (YoY +12.1%), Other ¥1,672,074 thousand (YoY +7.2%) |
| Segment profit | Arrhythmia business ¥1,100,966 thousand (YoY +7.9%), Ischemia business ¥119,327 thousand (YoY +7.7%), Other ¥215,449 thousand (YoY +17.7%) |
| Depreciation and amortization | ¥262,303 thousand |
| Impairment loss | None recorded (no applicable matter) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥2,168 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥0 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Name of newly added company Not disclosed / Excluded 0 / Excluded Company Name Not disclosed |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not applicable) |
| Issued Shares at Period-End | 10,780,000 shares |
| Treasury Shares at Period-End | 279,044 shares |
| Factors Behind Changes in Business Performance | Although selling, general and administrative expenses increased due to costs related to the management integration and personnel expenses resulting from wage increases, sales of catheters for PF ablation were strong. In the Arrhythmia business, sales of catheters for PF ablation were strong; in the Ischemia business, sales of balloon catheters and the RAQUOS injection system were strong; and in Other, sales of structural heart products, including TAVI products, were strong. |
Items this document does not state (10)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Selling, general and administrative expenses increased due to costs related to the management integration and personnel expenses resulting from wage increases, while sales of catheters for PF ablation were strong.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.